These limitations on the maximal theoretical efficacy of AAV gene therapy for DMD may result in the continued need for additional small molecule-based management of cardiomyopathy in the setting of an otherwise mild BMD-like phenotype. The gene discussed is DMD; the disease is cardiomyopathy.